Exelixis, Inc. (NASDAQ:EXEL) Director George A. Scangos sold 5,000 shares of Exelixis stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the director now owns 1,318,031 shares in the company, valued at approximately $32,950,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

EXEL stock opened at $24.53 on Monday. The company has a current ratio of 8.50, a quick ratio of 8.41 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $7.45 billion, a P/E ratio of 17.15, a PEG ratio of 0.77 and a beta of 2.22. Exelixis, Inc. has a 12-month low of $13.42 and a 12-month high of $25.19.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 12th. The biotechnology company reported $0.37 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.14. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. The company had revenue of $228.60 million for the quarter, compared to the consensus estimate of $188.44 million. During the same quarter in the prior year, the business earned $0.12 EPS. Exelixis’s revenue was up 90.4% on a year-over-year basis. On average, research analysts expect that Exelixis, Inc. will post 1.04 EPS for the current year.

A number of equities research analysts have commented on EXEL shares. ValuEngine downgraded Exelixis from a “hold” rating to a “sell” rating in a research report on Saturday, January 19th. Zacks Investment Research upgraded Exelixis from a “strong sell” rating to a “hold” rating in a research report on Monday, March 4th. BMO Capital Markets began coverage on Exelixis in a research report on Friday, February 22nd. They issued a “market perform” rating and a $23.00 target price on the stock. Cowen reiterated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a report on Tuesday, February 26th. Finally, BidaskClub downgraded Exelixis from a “buy” rating to a “hold” rating in a report on Saturday, January 19th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $29.20.

A number of hedge funds and other institutional investors have recently modified their holdings of EXEL. Norges Bank purchased a new stake in Exelixis during the 4th quarter worth about $54,640,000. Oregon Public Employees Retirement Fund increased its holdings in Exelixis by 1,978.9% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,319,939 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 2,208,347 shares during the period. Fiera Capital Corp acquired a new position in shares of Exelixis during the 4th quarter worth about $39,370,000. BB Biotech AG boosted its position in shares of Exelixis by 162.7% during the 3rd quarter. BB Biotech AG now owns 2,785,000 shares of the biotechnology company’s stock worth $49,350,000 after acquiring an additional 1,725,000 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of Exelixis by 451.9% during the 4th quarter. Prudential Financial Inc. now owns 1,598,167 shares of the biotechnology company’s stock worth $31,435,000 after acquiring an additional 1,308,617 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2019/03/18/insider-selling-exelixis-inc-exel-director-sells-125000-00-in-stock.html.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Further Reading: What type of investment options does a Roth IRA provide?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.